|Chemical and physical data|
|Molar mass||343.46 g/mol g·mol−1|
|3D model (JSmol)|
ADBICA (also known as ADB-PICA) is a designer drug identified in synthetic cannabis blends in Japan in 2013. ADBICA had not previously been reported in the scientific literature prior to its sale as a component of synthetic cannabis blends. ADBICA features a carboxamide group at the 3-indole position, like SDB-001 and STS-135. The stereochemistry of the tert-butyl side-chain in the product is unresolved, though in a large series of indazole derivatives structurally similar to ADBICA that are disclosed in Pfizer patent WO 2009/106980, activity resides exclusively in the (S) enantiomers. ADBICA is a potent agonist of the CB1 receptor and CB2 receptor with a EC50 value of 0.69 nM and 1.8 nM respectively.
As of October 2015 ADBICA is a controlled substance in China.
|This cannabinoid related article is a stub. You can help Wikipedia by expanding it.|